Research programme: anticancer antibodies - AbGenomics

Drug Profile

Research programme: anticancer antibodies - AbGenomics

Alternative Names: AbGn-100; AbGn-107; AbGn-108; AbGn-109; AbGn-110; AbGn-150; Antibody-100; Antibody-107; Antibody-150; Antibody-8

Latest Information Update: 18 Sep 2016

Price : $50

At a glance

  • Originator AbGenomics Corporation
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Aug 2016 The US FDA accepts IND application for commencing a phase I trial of AbGn 107 in Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater)
  • 25 Mar 2016 Preclinical development is ongoing in USA
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top